Venmax Drugs Merger Vote: Key Details for 2026

Venmax Drugs & Pharmaceuticals Ltd has scheduled an equity shareholders' meeting for October 24, 2026, to consider the proposed amalgamation of Hatri Pharma Private Limited into the listed company. The meeting is being held under directions issued by the National Company Law Tribunal, Hyderabad Bench-II. For Venmax shareholders, the vote is a formal stage in the proposed transaction rather than the completion of the merger.

The meeting is set for 12:30 p.m. IST and will be conducted through video conferencing or other audio-visual means. Venmax has described the proposed combination as a move towards backward integration, vertical consolidation and operational efficiencies. The eventual outcome remains subject to the shareholder vote and subsequent approvals applicable under the scheme.

NCLT Order Moves Scheme to Shareholder Stage

Venmax disclosed that the NCLT Hyderabad Bench-II issued its order on September 7, 2026. The order directed the company to convene a meeting of its equity shareholders to consider the Scheme of Amalgamation. Hatri Pharma is identified as the transferor company, while Venmax Drugs & Pharmaceuticals is the transferee company.

The tribunal direction does not by itself complete the amalgamation. It advances the proposal to a court-convened shareholder approval process under the Companies Act, 2013. The company subsequently issued meeting-related disclosures under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Meeting Scheduled for October 24

The equity shareholders' meeting is scheduled for Saturday, October 24, 2026, at 12:30 p.m. IST. Although participation is virtual, Venmax's registered office in Hyderabad is specified as the venue for the meeting. This is a standard convention for meetings conducted through VC or OAVM.

The company published newspaper advertisements on September 24, 2026, convening the meeting in line with the NCLT direction. The meeting notice and explanatory statement have been made available through the company website, the BSE website and the CDSL e-voting portal. Notices are also to be sent electronically to shareholders with registered email addresses.

What Shareholders Will Consider

Shareholders will vote on whether to approve the Scheme of Amalgamation presented by the company. The documents are issued under Sections 230 and 232, read with Section 102, of the Companies Act, 2013. These provisions govern compromise, arrangement and amalgamation proposals and the accompanying shareholder disclosures.

According to the information provided by Venmax, approval requires a majority of shareholders representing three-fourths in value of the equity shareholders voting on the scheme. This threshold makes the value represented in the vote relevant, not only the number of shareholders who participate. Final implementation would still require NCLT sanction and any other applicable regulatory steps.

Proposed Share Exchange Terms

A disclosed term of the scheme concerns Hatri Pharma's equity shares. Hatri Pharma's 2.373 crore equity shares would be exchanged for an equal number of Venmax shares, subject to shareholder approval and subsequent approvals. Based on the share count stated in the disclosures, this represents a 1:1 share exchange.

The supplied disclosures do not provide a valuation, revenue figures, profit metrics or detailed financial performance data for the companies. Investors therefore have limited financial information in the reported announcements for assessing the transaction beyond the stated share exchange and business rationale. The meeting documents remain the primary source for shareholders reviewing the proposal.

Stated Rationale for the Amalgamation

Venmax has said the proposed amalgamation is intended to support backward integration, operational efficiencies and vertical consolidation. Backward integration generally refers to bringing activities earlier in a company's supply chain into the combined business structure. The company has linked the proposal to business integration and efficiency objectives.

The disclosures do not quantify expected cost savings, revenue gains or other financial benefits from the transaction. As a result, those stated objectives should be read as the company's rationale for the scheme rather than as confirmed financial outcomes. No financial performance metrics were disclosed in the September 24 newspaper-publication filing.

Shareholding Details Disclosed

Information provided with the merger-related coverage states that Hatri Pharma has 57 shareholders holding equity of ₹23.73 crore. All of those shareholders were stated to have consented to the scheme. Venmax's shareholding was reported as 89.54% public shareholding and 10.46% promoter group holding.

These figures provide context for the shareholder approval process, although the actual Venmax vote will determine whether the scheme clears the required threshold. The company has asked shareholders to attend and vote electronically. Remote e-voting was stated to be open from October 21 to October 23, 2026.

Key Dates and Transaction Data

Market Reference and Corporate Action

The corporate-action information lists October 24, 2026, as the record date for an Extraordinary General Meeting. It records an LTP of ₹14.98 on the announcement day and ₹15.17 on the record day. These prices are reference points from the supplied corporate-action data and do not establish the market's final view on the proposed amalgamation.

The available disclosures do not state a market-capitalisation impact, earnings impact or valuation effect from the transaction. Investors assessing the event would need to rely on the statutory scheme documents, the shareholder vote and later regulatory filings. The absence of disclosed financial projections limits conclusions about the merger's eventual effect on Venmax's operations or financial position.

Why the Vote Matters

The October 24 meeting is the immediate decision point in Venmax's proposed amalgamation process. A favourable shareholder vote at the prescribed threshold would allow the scheme to move towards the next approval stages. If the required approval is not obtained, the proposal cannot proceed in its stated form.

For Hatri Pharma shareholders, the disclosed arrangement provides for Venmax shares in exchange for their existing Hatri equity shares. For Venmax shareholders, the vote concerns whether the listed company should absorb Hatri Pharma under the terms placed before them. The process remains governed by the scheme, the Companies Act framework and the NCLT's subsequent consideration.

Next Confirmed Milestone

The scheduled shareholder meeting on October 24, 2026, is the next confirmed milestone disclosed by Venmax. The company is expected to report the outcome after shareholders vote on the scheme. Any implementation of the amalgamation would depend on the required approvals, including final NCLT sanction as applicable.

Until the meeting outcome and later approvals are disclosed, the proposal remains an amalgamation under consideration. The available information establishes the meeting date, the virtual format, the 1:1 share exchange based on 2.373 crore Hatri shares, and Venmax's stated integration rationale. It does not confirm completion of the merger or quantify its financial effects.